September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Long-term outcomes of anti-vascular endothelial growth factor treatment in East-Asian patients with myopic choroidal neovascularization
Author Affiliations & Notes
  • Wayne Macfadden
    Ophthalmology, Novartis Pharma AG, Basel, Switzerland
  • Adrian Skelly
    Ophthalmology, Novartis Ireland Limited, Dublin, Ireland
  • Footnotes
    Commercial Relationships   Wayne Macfadden, Novartis Pharma AG, Basel, Switzerland (E); Adrian Skelly, Novartis Ireland Limited, Dublin, Ireland (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 2142. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wayne Macfadden, Adrian Skelly; Long-term outcomes of anti-vascular endothelial growth factor treatment in East-Asian patients with myopic choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 2016;57(12):2142.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : To assess the long-term effectiveness and safety of anti-vascular endothelial growth factor (anti-VEGF) therapies in East-Asian patients treated for visual impairment due to myopic choroidal neovascularization (mCNV).

Methods : Post-RADIANCE was a non-interventional, observational, 36-month retrospective multicenter chart review conducted in a cohort of East-Asian patients with mCNV who completed the RADIANCE study (NCT01217944), had at least one follow-up visit after RADIANCE trial participation and whose medical records were available. Patients were excluded if they had participated in an interventional study after the RADIANCE final visit. Demographic and baseline clinical characteristics of patients included in the Post-RADIANCE study were retrieved from the RADIANCE study database. The primary outcome was mean best-corrected visual acuity (BCVA; letters) change (±standard deviation [SD]) from the baseline visit of the RADIANCE trial (Month 0) to each follow-up visit during the Post-RADIANCE observation period (Month 13–48). Secondary objectives were assessed during Post-RADIANCE observation period. These included mCNV recurrence in the study eye, treatment administrated in the study eye, and ocular adverse events (AEs).

Results : Forty-one patients were included in the study. At baseline, patients had a mean age of 55.1 (±13.5) years, majority were female (33 [80.5%]), and had a mean BCVA of 56.5 (±12.1). Mean changes in BCVA (±SD) from baseline to Month 12 and Month 48 were +14.3 (±11.4) (n=40; p<0.0001) and +16.3(±18.7) (n=16; p=0.0034), respectively. During the 36-month follow-up period, 7 (17.1%) patients required additional anti-VEGF treatments, 7 (17.1%) patients had mCNV recurrence and 4 (9.8%) patients had a second recurrence, and 5 (12.2%) experienced an AE with none considered to be serious or related to anti-VEGF treatment.

Conclusions : BCVA gained at the end of the RADIANCE study was sustained over an additional 36 months of follow-up in East-Asian patients, during which time most patients did not require any further anti-VEGF treatment and no new safety concerns were observed.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.